India Globalization Capita Just Got FDA Approval To Start Enrolling Their Phase 2 Alzheimer Trial With IGC-AD1, A Cannabis Drug
https://clinicaltrials.gov/ct2/show/NCT05543681
Brief Summary:
This is a superiority, parallel group, double blinded, randomized, powered, multi-site, and placebo-controlled study.
Ages 60 and above
Quince Therapeutics Presents Preclinical Data At MHSRS 2022 Demonstrating Preclinical Efficacy Of Bone-targeting Platform For Traumatic Bone Injury
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company's participation at
Amry Announced CHMP Adopts Positive Opinion for Mycapssa for the Treatment of Acromegaly
Amryt (Nasdaq: AMYT) is pleased to announce that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Mycapssa® in the European Union (EU) for the maintenance treatment of acromegaly in patients who have responded to and to
Sanofi Announced CHMP Recommended Approval of Beyfortus for Prevention of RSV Disease in Infants
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus® (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
AstraZeneca Announced Evusheld Long-acting Antibody Combination Recommended for Approval in the EU for the Treatment of COVID-19
AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…
Sorrento Announces The Publication In The Nature Journal Scientific Reports The Details Of The Discovery Of SARS-CoV-2 Neutralizing Antibodies From The G-MAB Library
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento
Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2022)6734&lang=en
FDA Approves Edwards Lifesciences’ PASCAL Precision Transcatheter Valve Repair System For Most Frequent Cardiovascular Disorder
The FDA has approved Edwards Lifesciences Corp’s (NYSE:EW) PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) for degenerative…